Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic utility of immunohistochemical panel in various thyroid pathologies

  • Original Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Background

For management of thyroid nodules, distinction between benign and malignant tumours is essential. The study was performed to evaluate the diagnostic value of molecular markers in different thyroid tumours.

Materials and methods

Immunohistochemistry for CD56, HBME-1, COX-2, Ki-67, p53 and E-cadherin (E-CAD) was performed in 113 benign and 35 malignant thyroid lesions including 36 follicular adenomas (FA), 77 colloid goitres, 26 papillary thyroid carcinomas (PTC) and 9 follicular carcinomas (FC). The results were scored semiquantitatively by staining intensity (0–3 scale) and percentage of positive cells.

Results

PTC was characterised by decreased E-CAD and CD56 expression in contrast to surrounding benign thyroid tissues. HBME-1 expression was absent in benign thyroid tissues but was notably high in PTC and occasionally in FC. The expression of E-CAD and CD56 in FA was significantly higher than in the surrounding thyroid tissues. No expression of p53 was found in any group. The expression of COX-2 was low in all lesions. The proliferation activity by Ki-67 was generally low; however, it was significantly higher in cancers.

Conclusions

The panel consisting of three markers, HBME-1, E-CAD and CD56, can be recommended as an adjunct to morphology criteria. HBME-1 is found in malignant lesions only and is the most sensitive and specific single marker in PTC. Decreased expression of E-CAD and CD56 distinguishes PTC from FA and FC. Both FA and FC are characterised by high expression of E-CAD and CD56. The practical use of Ki-67 is difficult due to low values. The role of adhesion factors in thyroid malignancies may be superior in comparison with cell proliferation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Gharib H, Papini E (2007) Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin N Am 36:707–735

    Article  CAS  Google Scholar 

  2. Topliss D (2004) Thyroid incidentaloma: the ignorant in pursuit of the impalpable. Clin Endocrinol (Oxf) 60:18–20

    Article  Google Scholar 

  3. Hundahl SA et al (1998) A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 83:2638–2648

    Article  CAS  PubMed  Google Scholar 

  4. Finley DJ et al (2004) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214–3223

    Article  CAS  PubMed  Google Scholar 

  5. Liu YY et al (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 158:375–384

    Article  CAS  PubMed  Google Scholar 

  6. Haugen BR, Woodmansee WW, McDermott MT (2002) Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf) 56:281–290

    Article  CAS  Google Scholar 

  7. Bancroft JD, Gamble M (2003) Theory and practice of histological techniques, international edition. Churchill Livingstone, Edinburgh

    Google Scholar 

  8. DeLellis RA (2006) Pathology and genetics of thyroid carcinoma. J Surg Oncol 94:662–669

    Article  CAS  PubMed  Google Scholar 

  9. Altman DG, Machin D, Bryant TN, Gardner MJ (2005) Statistics with confidence, 2nd edn. BMJ, Bristol

    Google Scholar 

  10. Sheibani K et al (1992) Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 23:107–116

    Article  CAS  PubMed  Google Scholar 

  11. Saleh HA et al (2010) Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 5:9

    Article  PubMed  Google Scholar 

  12. Miettinen M, Karkkainen P (1996) Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity malignant tumours. Virchows Arch 429:213–219

    Article  CAS  PubMed  Google Scholar 

  13. Sack MJ et al (1997) HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10:668–674

    CAS  PubMed  Google Scholar 

  14. Mai KT et al (2002) Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40:133–142

    Article  CAS  PubMed  Google Scholar 

  15. Ito Y et al (2005) HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res 25:179–182

    CAS  PubMed  Google Scholar 

  16. Papotti M et al (2005) Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541–546

    Article  CAS  PubMed  Google Scholar 

  17. Prasad ML et al (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48–57

    Article  CAS  PubMed  Google Scholar 

  18. Rossi ED et al (2006) Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48:795–800

    Article  CAS  PubMed  Google Scholar 

  19. Saggiorato E et al (2005) Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12:305–317

    Article  CAS  PubMed  Google Scholar 

  20. de Micco et al (2008) Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer 98:818–823

    Article  PubMed  Google Scholar 

  21. Nasr MR et al (2006) Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol 19:1631–1637

    Article  CAS  PubMed  Google Scholar 

  22. Saleh HA et al (2009) Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal 6:18

    Article  PubMed  Google Scholar 

  23. Nga ME et al (2008) HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 36:550–556

    Article  PubMed  Google Scholar 

  24. Scognamiglio T et al (2006) Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708

    Article  CAS  PubMed  Google Scholar 

  25. Mase T et al (2003) HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50:173–177

    Article  PubMed  Google Scholar 

  26. Park YJ et al (2007) Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22:621–628

    Article  PubMed  Google Scholar 

  27. Zeromski J et al (1992) Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium. Clin Exp Immunol 89:474–478

    Article  CAS  PubMed  Google Scholar 

  28. El Demellawy D, Nasr A, Alowami S (2009) An updated review on the clinicopathologic aspects of arrhythmogenic right ventricular cardiomyopathy. Am J Forensic Med Pathol 30:78–83

    Article  PubMed  Google Scholar 

  29. El Demellawy D, Nasr A, Alowami S (2008) Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 3:5

    Article  PubMed  Google Scholar 

  30. Scarpino S et al (2007) Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 212:411–419

    Article  CAS  PubMed  Google Scholar 

  31. Hirohashi S, Kanai Y (2003) Cell adhesion system and human cancer morphogenesis. Cancer Sci 94:575–581

    Article  CAS  PubMed  Google Scholar 

  32. Eidelman S et al (1989) Expression of the cell-cell adhesion glycoprotein cell-CAM 120/80 in normal human tissues and tumors. Am J Pathol 135:101–110

    CAS  PubMed  Google Scholar 

  33. Brabant G et al (1993) E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 53:4987–4993

    CAS  PubMed  Google Scholar 

  34. Soares P et al (1997) E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer 70:32–38

    Article  CAS  PubMed  Google Scholar 

  35. von Wasielewski R et al (1997) Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57:2501–2507

    Google Scholar 

  36. Graff JR et al (1998) Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 58:2063–2066

    CAS  PubMed  Google Scholar 

  37. Choi YL et al (2005) Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci 20:853–859

    Article  CAS  PubMed  Google Scholar 

  38. Smyth P et al (2001) Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms. Int J Surg Pathol 9:265–272

    Article  CAS  PubMed  Google Scholar 

  39. Fosslien E (2000) Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30:3–21

    CAS  PubMed  Google Scholar 

  40. Ito Y et al (2003) Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 42:492–497

    Article  CAS  PubMed  Google Scholar 

  41. Specht MC et al (2002) Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 87:358–363

    Article  CAS  PubMed  Google Scholar 

  42. Casey MB et al (2004) Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions. Endocr Pathol 15:107–116

    Article  CAS  PubMed  Google Scholar 

  43. Cornetta AJ et al (2002) Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 112:238–242

    Article  CAS  PubMed  Google Scholar 

  44. Kim SJ et al (2003) Immunohistochemical expression of COX-2 in thyroid nodules. Korean J Intern Med 18:225–229

    CAS  PubMed  Google Scholar 

  45. Nose F et al (2002) Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am J Clin Pathol 117:546–551

    Article  CAS  PubMed  Google Scholar 

  46. Haynik DM, Prayson RA (2005) Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid. Arch Pathol Lab Med 129:736–741

    CAS  PubMed  Google Scholar 

  47. Saad AG et al (2006) Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab 91:2672–2677

    Article  CAS  PubMed  Google Scholar 

  48. Ziad el A et al (2008) Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving. Folia Histochem Cytobiol 46:461–464

    Article  PubMed  Google Scholar 

  49. Novosel I et al (2006) p53, bcl-2 and Ki-67 in the diagnosis of insular thyroid gland cancer. Case report with a review of literature. Lijec Vjesn 128:264–267

    PubMed  Google Scholar 

  50. Akslen LA, Varhaug JE (1995) Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 76:1643–1654

    Article  CAS  PubMed  Google Scholar 

  51. Martinez J, Georgoff I, Levine AJ (1991) Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5:151–159

    Article  CAS  PubMed  Google Scholar 

  52. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093

    Article  CAS  PubMed  Google Scholar 

  53. Morita N, Ikeda Y, Takami H (2008) Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg 32:2617–2622

    Article  PubMed  Google Scholar 

  54. Dobashi Y et al (1993) Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375–381

    Article  CAS  PubMed  Google Scholar 

  55. Chen BK et al (1999) Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 15:893–898

    CAS  PubMed  Google Scholar 

  56. Kobayashi T et al (1995) Clinicopathological findings and p53 expression of thyroid cancer in children. Surg Today 25:217–221

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The study was supported by grant 2009/0147/1DP/1.1.2.1.2/09/IPIA/VIAA/009 from European Social Fund.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Surgery, Pauls Stradins University Hospital, Pilsonu 13, 1004, Riga, Latvia

    Arturs Ozolins, Zenons Narbuts & Janis Gardovskis

  2. Department of Surgery, Riga Stradins University, Riga, Latvia

    Arturs Ozolins, Zenons Narbuts & Janis Gardovskis

  3. Department of Pathology, Riga Stradins University, Riga, Latvia

    Ilze Strumfa

  4. Faculty of Continuing Education, Riga Stradins University, Riga, Latvia

    Guna Volanska

Authors
  1. Arturs Ozolins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zenons Narbuts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilze Strumfa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guna Volanska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janis Gardovskis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arturs Ozolins.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozolins, A., Narbuts, Z., Strumfa, I. et al. Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg 395, 885–891 (2010). https://doi.org/10.1007/s00423-010-0690-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-010-0690-6

Keywords

Search

Navigation